Patterns of care in prostate cancer (PCa) have changed tremendously in the past 20 years, altering the way patients with this tumor present and how they are evaluated before and after diagnosis. With the use of new and combined treatments, the frequency and variety of complications have differed from those previously reported. Advances have been made in PCa imaging, biopsy methodology, in understanding causative factors and disease, in treatment-related quality of life, and in predicting the behavior of individual tumors using risk strata. Despite these advances, no consensus has emerged regarding the optimal treatment for the most common patient with PCa.
There is a need for oncologists, urologists, and nurses to understand the rationale behind targeted therapy for the treatment of advanced PCa, and how trial entry could improve the efficacy of drugs and decrease the toxicity. This activity seeks to educate urologists and other healthcare professionals about the latest advances in the prevention, screening, and treatment of PCa. The International Prostate Cancer Update (IPCU) educational planning committee has identified the following educational gaps between recent research in PCa and its integration into professional practice at the international, national, and community levels:
Current best practices in prevention and screening of PCa
Promising therapies, issues, and economic concerns in the treatment of local disease
Role of newly available therapies in 2014
Emerging treatment options for localized, advanced, and castration-resistant PCa
The 23rd International Prostate Cancer Update Wednesday, January 23, 2013 - Saturday, January 26, 2013